Home
Disease Knowledge Center Drug Hub Monographs Drug Interactions Pregnancy Drug Safety Drug Recalls & Alerts OTC Navigator
Virtual Simulators Hub Clinical Cases Simulator Nutrition & Macro Calculator
Questo Insights Global Opportunities Hub AI Research Assistant Citation & Reference Generator Scholarships & Essay Planner Visa & Mobility Navigator English Assessment Test
Verified Jobs Board Pharmacy Clearance Pharmacies Directory
Practice Quizzes STEM Academy Toolkits
Medical Case Donations Opportunity Crowdfunding Community Forums Courses Academy
Back to Safety Checker

Ibuprofen

Nonsteroidal Anti-Inflammatory Drug (NSAID)

FDA Category C (<20 wks) / FDA Category D (>=20 wks) FDA Warning
Avoid — Contraindicated After 20 Weeks

Ibuprofen must be avoided starting at 20 weeks gestation due to serious risks of premature closure of the fetal ductus arteriosus and fetal renal dysfunction causing severe oligohydramnios.

Medical Disclaimer: This report is for educational and informational purposes only. It does not replace professional medical advice. Always consult your healthcare provider before making any medication decisions during pregnancy.
Pregnancy Summary
Clinical overview for pregnancy

FDA drug safety warning (2020) strictly warns against NSAID use at 20 weeks or later. Prostaglandin inhibition impairs fetal renal blood flow and vascular constriction.

Trimester Safety Timeline
Safety profile across all three trimesters
1st Trimester
Weeks 1 – 12
Use With Caution

Some observational studies link early exposure near conception with a slight increase in miscarriage risk.

2nd Trimester
Weeks 13 – 27
Avoid (>=20 Wks)

Contraindicated starting at week 20. Causes fetal kidney impairment and low amniotic fluid.

3rd Trimester
Weeks 28 – Birth
Contraindicated

Strictly contraindicated. Causes premature closure of fetal ductus arteriosus and persistent pulmonary hypertension.

Placental Transfer
Does this medication cross the placenta?
Crosses Placenta
Yes
Transfer Extent
High (Crosses placenta extensively)

Directly inhibits fetal prostaglandin synthesis, altering fetal circulation and kidney function.

Fetal Risk Assessment
Potential effects on the developing fetus
Premature Ductus Arteriosus Closure

Inhibits prostacyclin, causing vascular constriction of fetal ductus arteriosus and persistent pulmonary hypertension.

Fetal Renal Dysfunction & Oligohydramnios

Reduces fetal renal blood flow starting at 20 weeks, causing severe oligohydramnios within days.

Maternal Risk Assessment
Potential maternal side effects during pregnancy
Prolonged Labor & Hemorrhage

Inhibits uterine contractions leading to delayed labor and peripartum bleeding risk.

Clinical Recommendation
Professional prescribing guidance
Avoid — Switch to Acetaminophen

Do not prescribe or take ibuprofen at >= 20 weeks gestation. Use acetaminophen as a safer alternative.

If Already Taken
"I took this before knowing I was pregnant"
1
Discontinue Immediately

Stop taking ibuprofen and switch to acetaminophen for pain relief.

Pregnancy Monitoring Protocol
Recommended follow-up and surveillance
Ultrasound Surveillance
  • Amniotic Fluid Index (AFI) check if exposed >=20 weeks for >48 hrs
Safer Alternatives
Active ingredients with better pregnancy safety profiles
acetaminophen
First-line safe analgesic/antipyretic across all trimesters.
Safe
Professional Clinical Notes
Key prescribing considerations and clinical pearls
  • FDA Warning (2020): Avoid NSAIDs in pregnancy at 20 weeks or later.
Patient-Friendly Explanation
In simple, easy-to-understand language
Easy to Understand

Do not take ibuprofen during pregnancy, especially after 20 weeks. Use acetaminophen instead.

Frequently Asked Questions
Common questions about Ibuprofen in pregnancy

After 20 weeks, ibuprofen can reduce fetal urine production causing low amniotic fluid.

Evidence Level
Quality of available safety data
FDA Warning

Supported by FDA Drug Safety Communications and ACOG guidelines.

References & Primary Sources
Official U.S. Food & Drug Administration (FDA) PLLR & ACOG Clinical Database
All pregnancy safety evaluations, risk categories, and drug monographs are compiled directly from U.S. FDA Pregnancy and Lactation Labeling Rule (PLLR) standards and approved FDA prescribing labels.
  1. 1
    U.S. Food and Drug Administration (FDA) PLLR — FDA Pregnancy and Lactation Labeling Rule & Approved Prescribing Information Database Last updated: Official FDA Standard
  2. 2
    FDA Center for Drug Evaluation and Research (CDER) — FDA MedWatch & Black Box Warning Database Last updated: Official FDA Standard
  3. 3
    ACOG Practice Bulletins & Guidelines — American College of Obstetricians and Gynecologists Clinical Recommendations Last updated: 2025 Clinical Edition
  4. 4
    Briggs Drugs in Pregnancy and Lactation — Reference Guide to Fetal and Neonatal Risk (12th Edition) Last updated: 2025 Clinical Edition
Search Another Medication

System Notice

Confirm Action